{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"32.3","value":"19"},{"comment":"Within the study's follow-up period, less than half of the patients have experienced relapse, so a median RFS hasn't been statistically determined","groupId":"OG001","lowerLimit":"31.0","upperLimit":"34.6","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Relapse-free survival is the time from documented CR/CRi until relapse or death.","dispersionType":"Full Range","groups":[{"description":"INDUCTION (CYCLE 1): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-28, and trametinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION (CYCLES 2-24): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-21, and trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given IV or SC\n\nTrametinib: Given PO\n\nVenetoclax: Given PO","id":"OG000","title":"Cohort A (Newly Diagnosed AML Patients)"},{"description":"INDUCTION (CYCLE 1): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-28, and trametinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION (CYCLES 2-24): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-21, and trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given IV or SC\n\nTrametinib: Given PO\n\nVenetoclax: Given PO","id":"OG001","title":"Cohort B (Relapsed/Refractory AML or Higher-risk MDS or CMML Patients)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From documented CR/CRi until relapse or death, assessed until study completion","title":"Relapse-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}